Peter A. Thompson bought $10M of EWTX
director, owner at Edgewise Therapeutics, Inc.. 496,771 shares at an average of $20.13, traded Apr 3, 2025, filed Apr 4, 2025.
Score components
- +15RoleDirector
- +25Trade size$10.0M at market
- 0Relative to holdingsHoldings up 3.4%
- +18Price context0% above the 52-week low; 63% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-25-000360, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 3, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +372,578 | $20.13 | $7.5M | 14,809,075 | Apr 4, 2025 |
| Apr 3, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +124,193 | $20.13 | $2.5M | 443,792 | Apr 4, 2025 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Edgewise Therapeutics, Inc. | R Michael Carruthers Chief Financial Officer | $22k 1,314 shares | -2% | |
| 20Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $28k 1,691 shares | -8% | |
| 29Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $85k 5,187 shares | -19% | |
| 38Weak | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $70k 4,276 shares | -17% | |
| 25Weak | Edgewise Therapeutics, Inc. | John R Moore General Counsel | $32k 1,930 shares | -23% | |
| 20Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $26k 1,551 shares | -8% | |
| 66Notable | Edgewise Therapeutics, Inc. | Orbimed Advisors LLC director, owner | $10M 496,771 shares | +3% | |
| 0Weak | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $3,000 100 shares | -1% | |
| 0Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $6,004 200 shares | -1% | |
| 19Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $300k 10,000 shares | -37% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.